Riggins N, et al. - In this small pilot study, researchers evaluated the prophylactic effectiveness of an intravenous (IV) valproate sodium, an anti-epileptic and mood stabilizer, for migraine in cases with chronic migraine refractory to multiple preventive medications. Fourteen cases with chronic migraine were admitted for a 4-day course of IV valproate sodium and were administered 250 mg of valproate sodium over a standard infusion time of 60 minutes every 8 hours. This small pilot study had promising outcomes for patient headache improvement. Further, cases with chronic migraine who were resistant to oral medications exhibited good tolerability towards this repetitive dosing valproate sodium protocol.